Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Halozyme Therapeutics, Inc.'s quarterly P/E stands at 13.2x, down 22.8% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 22.9% YoY to 11.2x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 26.78 | 13.24 | — | 12.82 | 9.78 | 17.15 | 11.28 | 13.63 | 18.18 | 16.95 | 14.22 | 15.66 | 16.10 |
| — | -22.8% | — | -5.9% | -46.2% | +1.2% | -20.7% | -12.9% | +12.9% | -48.5% | -58.0% | -30.3% | -76.6% | |
| P/S Ratio | 5.82 | 5.27 | 4.38 | 6.33 | 4.96 | 7.63 | 5.19 | 6.42 | 7.31 | 6.69 | 5.26 | 5.93 | 5.45 |
| — | -30.9% | -15.6% | -1.4% | -32.2% | +14.0% | -1.4% | +8.3% | +34.2% | -17.6% | -51.5% | -10.1% | -46.9% | |
| P/B Ratio | 174.00 | 36.16 | 162.23 | 17.80 | 19.41 | 16.76 | 17.01 | 16.45 | 23.38 | 29.49 | 57.79 | 20.56 | 31.89 |
| — | +115.8% | +853.9% | +8.2% | -17.0% | -43.2% | -70.6% | -20.0% | -26.7% | -63.1% | +24.4% | -63.8% | +49.4% | |
| P/FCF | 12.61 | 11.26 | 9.10 | 12.78 | 16.45 | 13.18 | 8.82 | 16.36 | 31.79 | 10.41 | 12.14 | 9.89 | 17.59 |
| — | -14.6% | +3.2% | -21.9% | -48.2% | +26.6% | -27.3% | +65.4% | +80.7% | -40.2% | -50.7% | -50.7% | -55.9% | |
| EV / EBITDA | 11.21 | 11.20 | 8.83 | 10.55 | 8.87 | 14.53 | 9.67 | 11.98 | 14.68 | 14.21 | 12.78 | 14.25 | 13.23 |
| — | -22.9% | -8.7% | -11.9% | -39.6% | +2.2% | -24.4% | -15.9% | +11.0% | -36.7% | -54.4% | -6.7% | -66.8% | |
| EV / EBIT | 12.42 | 13.25 | 9.76 | 11.54 | 9.76 | 16.63 | 10.37 | 12.96 | 17.23 | 17.22 | 14.62 | 14.93 | 15.60 |
| — | -20.3% | -5.9% | -11.0% | -43.3% | -3.4% | -29.1% | -13.2% | +10.5% | -41.3% | -51.9% | -29.4% | -72.1% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Halozyme Therapeutics, Inc.'s operating margin was 49.0% in Q1 2026, down 7.3 pp QoQ and down 4.5 pp YoY. This marks the 4th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 57.2% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 5.2% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.1% | 71.1% | 77.4% | 79.4% | 80.3% | 75.0% | 85.9% | 83.0% | 75.2% | 76.5% | 77.3% | 74.6% | 77.3% |
| — | -5.2% | -9.9% | -4.3% | +6.8% | -1.9% | +11.2% | +11.2% | -2.8% | -2.3% | +0.6% | -3.5% | -0.5% | |
| Operating Margin | 58.4% | 49.0% | 56.3% | 61.5% | 62.2% | 53.4% | 58.9% | 56.3% | 50.7% | 48.8% | 43.9% | 40.9% | 42.7% |
| — | -8.3% | -4.4% | +9.3% | +22.7% | +9.6% | +34.1% | +37.7% | +18.6% | +47.0% | +7.0% | +2.5% | +91.2% | |
| Net Margin | 22.7% | 39.8% | -31.3% | 49.5% | 50.7% | 44.6% | 46.0% | 47.2% | 40.3% | 39.2% | 37.1% | 37.9% | 33.8% |
| — | -10.7% | -168.2% | +4.7% | +25.8% | +13.7% | +23.9% | +24.7% | +19.2% | +60.5% | +16.8% | +28.4% | +127.2% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 153.6% | 111.8% | -51.2% | 41.9% | 40.5% | 27.9% | 33.6% | 36.9% | 39.9% | 58.7% | 51.3% | 40.9% | 68.9% |
| — | +300.5% | -252.7% | +13.4% | +1.5% | -52.5% | -34.6% | -9.7% | -42.1% | +74.7% | +18.6% | +29.4% | +740.9% | |
| ROA | 13.8% | 5.8% | -6.0% | 8.2% | 7.8% | 5.5% | 6.6% | 6.7% | 4.9% | 4.3% | 4.7% | 4.4% | 4.3% |
| — | +4.1% | -191.0% | +22.3% | +58.8% | +29.0% | +39.1% | +51.7% | +14.9% | +92.1% | +51.3% | +30.7% | +176.4% | |
| ROIC | 32.1% | 6.7% | 10.4% | 9.7% | 8.5% | 6.0% | 7.4% | 7.2% | 5.6% | 4.8% | 5.2% | 4.6% | 4.9% |
| — | +13.1% | +41.1% | +34.8% | +49.8% | +23.7% | +43.5% | +57.3% | +15.0% | +73.2% | +33.7% | +6.1% | +136.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Halozyme Therapeutics, Inc.'s Debt/EBITDA ratio is 9.8x, up from 7.6x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 67.1% YoY to 2.76x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 43.89 | 9.76 | 43.89 | 3.00 | 4.54 | 3.13 | 4.14 | 3.32 | 5.19 | 8.44 | 17.89 | 6.01 | 9.91 |
| — | +212.4% | +960.5% | -9.8% | -12.6% | -63.0% | -76.9% | -44.7% | -47.6% | -62.8% | +101.7% | -61.3% | +133.0% | |
| Debt / EBITDA | 2.37 | 9.83 | 7.62 | 6.34 | 6.77 | 9.31 | 7.69 | 8.19 | 10.92 | 12.97 | 12.32 | 13.45 | 13.00 |
| — | +5.6% | -0.8% | -22.7% | -38.0% | -28.2% | -37.6% | -39.1% | -16.0% | -35.6% | -33.3% | +0.6% | -51.4% | |
| Current Ratio | 4.66 | 2.76 | 4.66 | 1.59 | 8.36 | 8.39 | 7.80 | 10.36 | 7.41 | 6.64 | 6.64 | 7.63 | 6.58 |
| — | -67.1% | -40.3% | -84.7% | +12.9% | +26.5% | +17.6% | +35.7% | +12.6% | -0.8% | +17.4% | +27.8% | +142.2% | |
| Quick Ratio | 3.66 | 2.33 | 3.66 | 1.37 | 7.01 | 7.30 | 6.78 | 9.15 | 6.21 | 5.36 | 5.50 | 6.51 | 5.44 |
| — | -68.0% | -46.0% | -85.1% | +12.8% | +36.2% | +23.3% | +40.5% | +14.2% | -3.0% | +12.6% | +29.5% | +144.3% | |
| Interest Coverage | 45.03 | 33.50 | 51.80 | 50.73 | 46.07 | 31.28 | 40.25 | 37.50 | 25.91 | 21.20 | 20.38 | 23.59 | 21.73 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HALO stock.
Halozyme Therapeutics, Inc.'s current P/E is 26.8x. The average P/E over the last 3 quarters is 11.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Halozyme Therapeutics, Inc.'s current operating margin is 58.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Halozyme Therapeutics, Inc.'s business trajectory between earnings reports.